NCT07203391View on ClinicalTrials.gov

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2029

Conditions
Uveal Melanoma, Metastatic
Interventions
DRUG

roginolisib

Investigational combination - initially at 40mg (Dose 1) then 80mg (Dose 2)

Trial Locations (2)

2010

RECRUITING

St Vincents Hospital, Sydney

Unknown

NOT_YET_RECRUITING

Alfred Hospital, Melbourne

All Listed Sponsors
lead

St Vincent's Hospital, Sydney

OTHER